New CloudBlue Connect Delivers Omni-Product Platform that Unifies Multiple Channels
CloudBlue, an Ingram Micro business, today announced the global launch of CloudBlue ConnectTM, an omni-product platform aimed at helping vendors and service providers expand their reach and decrease time to market with minimal overhead costs. The CloudBlue Connect platform is capable of helping a company use only one system to manage its go-to-market channels – direct and indirect – supporting both traditional and recurring digital products and services.
Furthermore, the platform automates many of the time-intensive tasks of managing a go-to-market channel, including contract management, maintaining product information, fulfillment, usage management and subscription services.
“Vendors and service providers have long been struggling to manage multiple integrations for their partnership and channel programs and have been forced to invest a huge amount of resources in development and maintenance,” said Tarik Faouzi, vice president of CloudBlue. “CloudBlue Connect alleviates these issues, freeing up vendors to focus on what they do best – innovate – while service providers are better-enabled to deliver more value to their customers.”
CloudBlue Connect is a single platform that centralizes relationships and standardizes integrations with the entire partner base through RESTful APIs. It runs 24/7 with automated processes to support the recurring revenue business of vendors and service providers across the globe. In addition, this commerce-agnostic platform can integrate with a company’s own or any third-party commerce system, which obviously includes the CloudBlue Commerce platform.
Key benefits include:
Unified channel management
CloudBlue Connect centralizes a business’ fulfillment operations with its partners and reduces integrations development and maintenance efforts to a single system.
Businesses can reduce the time and resources spent on establishing an indirect channel presence and managing channel fulfillment requests with innovative go-to-market automation and a hyperscale platform, allowing them to build a scalable business.
Exponentially broadened reach
Vendors and other IP creators can boost their connections in any market around the globe in less time by tapping into CloudBlue Connect’s ecosystem of more than 200 service providers and a potential reach of more than 2 billion end customers.
Fast-tracked time to market
By simplifying and streamlining your multichannel fulfillment, businesses can cut down on back-office operations and get to market faster.
Reduction of channel maintenance costs
The total cost of ownership to build and manage integrations with multiple channel partners can be cut by upwards of $2 million over three years, according to a study by Forrester.*
In addition to supporting independent software vendors (ISVs), CloudBlue Connect’s capabilities extend to other vendors, including original equipment manufacturers (OEMs) and other partners looking to digitize and monetize their own IP. These vendors can use CloudBlue Connect as a channel enablement engine to go to market with their own IP services and products, expanding into any business or consumer markets at low costs.
On the downstream side of the platform, service providers can start transacting with vendors in CloudBlue Connect or integrate new vendors with a few clicks. This allows for additional bundling and cross-selling opportunities with their customers, creating stickiness and reducing churn. The versatility of CloudBlue Connect allows service providers to more closely define anything as a service for any product they have now or anything they dream up in the future. Service providers can also white-label Connect as their onboarding platform to onboard any additional vendors.
Faouzi concluded, “CloudBlue Connect is the perfect companion for the CloudBlue Commerce platform, along with Go-to-Market Automator, and allows vendors and service providers to enable the end-to-end management of their subscription business.”
*Cormier, Bob. “The Total Economic Impact of the CloudBlue Enterprise Commerce Platform Powered by Microsoft Azure. Forrester Consulting. April 2019.
CloudBlue is dedicated to helping service providers of all kinds build, scale and monetize cloud and digital services in the “as-a-service” economy. Many of the world’s best-known telecommunications companies, technology distributors, managed services providers, and value-added resellers rely on CloudBlue’s leading commerce platform to automate, aggregate and sell both their own cloud services, as well as those from third-party vendors. CloudBlue powers more than 200 of the world’s largest service provider cloud marketplaces, which collectively represent more than 30 million enterprise cloud subscriptions and over $1B in annual subscription revenue. CloudBlue provides its customers access to an ecosystem that includes more than 250 vendor solutions and more than 80,000 resellers around the world. CloudBlue is an independent software division of Ingram Micro. More at www.cloudblue.com.
Global Media Contact:
CloudBlue and Ingram Micro Cloud
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma
Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu
Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EET | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer
BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EET | Press release
BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom